Cristina Castells-Sala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cristina Castells-Sala has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Maria Luisa Pérez
Barcelona Tissue Bank, Banc de Sang i Teixits (BST), Barcelona, Spain
3 shared publications A. Aiti
Barcelona Tissue Bank, Banc de Sang i Teixits (BST), Barcelona, Spain
2 shared publicationsA. Vilarrodona
Barcelona Tissue Bank, Banc de Sang i Teixits (BST), Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau; SGR1113), Barcelona, Spain
2 shared publications- Anna Vilarrodona
Barcelona Tissue Bank, Banc de Sang i Teixits, 08005 Barcelona, Spain
2 shared publications O. Fariñas
Barcelona Tissue Bank, Banc de Sang i Teixits (BST), Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau; SGR1113), Barcelona, Spain
2 shared publications- Oscar Fariñas
Banc de Sang i Teixits de Catalunya, Barcelona (BST), 08005 Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 23 December 2025
- Published by SAGE Publications in Cell Transplantation
- Vol. 34
A narrative review of vascular conduits for coronary artery bypass grafting
Coronary artery bypass grafting (CABG) involves creating new conduits to restore blood flow to the heart. Using autologous vascular grafts presents challenges, including infection risk after vein harvesting, and scarcity of viable vein tissue. Researchers are exploring tissue-engineered vascular grafts (TEVGs), aiming to create optimal small-diameter vascular graft (SDVG) (<6 mm) for CABG surgery. TEVGs with suitable long-term patency could offer a promising alternative, potentially reduce patient morbidity and improve surgical outcomes. However, no SDVG is commercially available for CABG surgery in Europe, and no new clinical trials of coronary TEVGs have been reported since 2018. This narrative review summarizes the development and use of SDVG (<6 mm) for CABG, focusing on TEVGs and cell-seeding strategies. We outline the main types of grafts tested in preclinical and early clinical studies and highlight how different cell sources and seeding approaches aim to enhance graft functionality, patency, and long-term outcome.
- 23 December 2025
- Published by SAGE Publications in Cell Transplantation
- Vol. 34
Open AccessA narrative review of vascular conduits for coronary artery bypass grafting
Coronary artery bypass grafting (CABG) involves creating new conduits to restore blood flow to the heart. Using autologous vascular grafts presents challenges, including infection risk after vein harvesting, and scarcity of viable vein tissue. Researchers are exploring tissue-engineered vascular grafts (TEVGs), aiming to create optimal small-diameter vascular graft (SDVG) (<6 mm) for CABG surgery. TEVGs with suitable long-term patency could offer a promising alternative, potentially reduce patient morbidity and improve surgical outcomes. However, no SDVG is commercially available for CABG surgery in Europe, and no new clinical trials of coronary TEVGs have been reported since 2018. This narrative review summarizes the development and use of SDVG (<6 mm) for CABG, focusing on TEVGs and cell-seeding strategies. We outline the main types of grafts tested in preclinical and early clinical studies and highlight how different cell sources and seeding approaches aim to enhance graft functionality, patency, and long-term outcome.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 21, 209-228
Advancing Heart Valve Replacement: Risk Mitigation of Decellularized Pulmonary Valve Preparation for Its Implementation in Public Tissue Banks
Purpose: Cryopreserved homografts for valve replacement surgeries face a major problem regarding their durability after implantation and decellularized pulmonary heart valves have raised as potential new generation substitute for these surgeries. The present study aims to document the work performed for the safe implementation in public tissue banks of a new decellularization method for human pulmonary heart valves, based on previous risk evaluation. Methods: After assessing new preparation method associated risks, using EuroGTP-II methodologies, an extensive array of in vitro studies were defined to validate the new technique, mitigate the risks and provide quality and safety data. Results: Initial evaluation of risks using EuroGTP II tool, showed Final Risk Score of 23 (high risk), and four studies were devised to mitigate identified risks: (i) tissue structure integrity; (ii) cell content; (iii) microbiological safety; and (iv) cytotoxicity evaluation in final tissue preparation. Protein quantification, mechanical properties, and histological evaluation indicated no tissue damage, reducing implant failure probability, while cellular content removal demonstrated a 99% DNA removal and microbiological control ensured contamination absence. Moreover, in vitro results showed no cytotoxicity. Risk re-evaluation indicated a risk reduction to moderate risk (Final Risk Score = 10), suggesting that further evidence for safe clinical use would be needed at pre-clinical in vivo evaluation to mitigate remaining risks. Conclusions: The studies performed and reviewed bibliography were able to significantly reduce the original level of risk associated with the clinical application of this homograft’s preparation. However, additional in vivo studies and tissue stability tests are still necessary to address the remaining risks associated with reagents’ effect on extracellular matrix and storage conditions, which could influence implant failure, before the clinical evaluation procedures can be implemented to determine the efficacy and safety of the new decellularized heart valves.
- 1 February 2025
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 21, 209-228
Open AccessAdvancing Heart Valve Replacement: Risk Mitigation of Decellularized Pulmonary Valve Preparation for Its Implementation in Public Tissue Banks
Purpose: Cryopreserved homografts for valve replacement surgeries face a major problem regarding their durability after implantation and decellularized pulmonary heart valves have raised as potential new generation substitute for these surgeries. The present study aims to document the work performed for the safe implementation in public tissue banks of a new decellularization method for human pulmonary heart valves, based on previous risk evaluation. Methods: After assessing new preparation method associated risks, using EuroGTP-II methodologies, an extensive array of in vitro studies were defined to validate the new technique, mitigate the risks and provide quality and safety data. Results: Initial evaluation of risks using EuroGTP II tool, showed Final Risk Score of 23 (high risk), and four studies were devised to mitigate identified risks: (i) tissue structure integrity; (ii) cell content; (iii) microbiological safety; and (iv) cytotoxicity evaluation in final tissue preparation. Protein quantification, mechanical properties, and histological evaluation indicated no tissue damage, reducing implant failure probability, while cellular content removal demonstrated a 99% DNA removal and microbiological control ensured contamination absence. Moreover, in vitro results showed no cytotoxicity. Risk re-evaluation indicated a risk reduction to moderate risk (Final Risk Score = 10), suggesting that further evidence for safe clinical use would be needed at pre-clinical in vivo evaluation to mitigate remaining risks. Conclusions: The studies performed and reviewed bibliography were able to significantly reduce the original level of risk associated with the clinical application of this homograft’s preparation. However, additional in vivo studies and tissue stability tests are still necessary to address the remaining risks associated with reagents’ effect on extracellular matrix and storage conditions, which could influence implant failure, before the clinical evaluation procedures can be implemented to determine the efficacy and safety of the new decellularized heart valves.
- Open Access
- 10 September 2024
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (3) , 1819-1829
Pericardium decellularization in a one-day, two-step protocol
Scaffolds used in tissue engineering can be obtained from synthetic or natural materials, always focusing the effort on mimicking the extracellular matrix of human native tissue. In this study, a decellularization process is used to obtain an acellular, biocompatible non-cytotoxic human pericardium graft as a bio-substitute. An enzymatic and hypertonic method was used to decellularize the pericardium. Histological analyses were performed to determine the absence of cells and ensure the integrity of the extracellular matrix (ECM). In order to measure the effect of the decellularization process on the tissue’s biological and mechanical properties, residual genetic content and ECM biomolecules (collagen, elastin, and glycosaminoglycan) were quantified and the tissue’s tensile strength was tested. Preservation of the biomolecules, a residual genetic content below 50 ng/mg dry tissue, and maintenance of the histological structure provided evidence for the efficacy of the decellularization process, while preserving the ECM. Moreover, the acellular tissue retains its mechanical properties, as shown by the biomechanical tests. Our group has shown that the acellular pericardial matrix obtained through the super-fast decellularization protocol developed recently retains the desired biomechanical and structural properties, suggesting that it is suitable for a broad range of clinical indications.
- 10 September 2024
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (3) , 1819-1829
Open AccessPericardium decellularization in a one-day, two-step protocol
Scaffolds used in tissue engineering can be obtained from synthetic or natural materials, always focusing the effort on mimicking the extracellular matrix of human native tissue. In this study, a decellularization process is used to obtain an acellular, biocompatible non-cytotoxic human pericardium graft as a bio-substitute. An enzymatic and hypertonic method was used to decellularize the pericardium. Histological analyses were performed to determine the absence of cells and ensure the integrity of the extracellular matrix (ECM). In order to measure the effect of the decellularization process on the tissue’s biological and mechanical properties, residual genetic content and ECM biomolecules (collagen, elastin, and glycosaminoglycan) were quantified and the tissue’s tensile strength was tested. Preservation of the biomolecules, a residual genetic content below 50 ng/mg dry tissue, and maintenance of the histological structure provided evidence for the efficacy of the decellularization process, while preserving the ECM. Moreover, the acellular tissue retains its mechanical properties, as shown by the biomechanical tests. Our group has shown that the acellular pericardial matrix obtained through the super-fast decellularization protocol developed recently retains the desired biomechanical and structural properties, suggesting that it is suitable for a broad range of clinical indications.
- 17 March 2023
- Published by Elsevier in Transplant Immunology
- Vol. 78, 101825
Development of a full-thickness acellular dermal graft from human skin: Case report of first patient rotator cuff patch augmentation repair
- 17 March 2023
- Published by Elsevier in Transplant Immunology
- Vol. 78, 101825
Development of a full-thickness acellular dermal graft from human skin: Case report of first patient rotator cuff patch augmentation repair
- Open Access
- 27 February 2023
- Published by Springer Nature in Cell and Tissue Banking
- Vol. 25 (1) , 11-26
Last twenty-years activity of cardiovascular tissue banking in Barcelona
The Barcelona Tissue Bank was established from the merge of two previous multi-tissue banks. Potential donors are screened by Donor Center staff and multi-tissue retrieval is performed by specialized own teams. Tissue processing and preservation is performed in clean room facilities by specialised personnel. After quality control of both donor and all tissues results, the heart valves and vascular segments are stored until medical request. The aim of this report is to present the cardiovascular tissue activity and retrospectively evaluate the outcomes of the changes performed in last 20 years. Cardiovascular tissue from 4088 donors was received, specifically 3115 hearts and 2095 vascular segments were processed and evaluated. A total of 48% of the aortic valves, 68% of the pulmonary valves and 75% of the vascular segments were suitable for transplant. The main reason for discarding tissue was macroscopic morphology followed by microbiological results, for both valves and arteries. Altogether, 4360 tissues were distributed for transplantation: 2032 (47%) vascular segments, 1545 (35%) pulmonary valves and 781 (18%) aortic valves. The most common indication for aortic valve surgery was the treatment of endocarditis, while for pulmonary valves, it was congenital malformation reconstruction. Vascular segments were mainly used for reconstruction after ischemia. During this period, a number of changes were made with the goal of enhancing tissue quality, safety and efficacy. These improvements were achieved through the use of a new antibiotic cocktail, increasing of donor age criteria and changing the microbiological control strategy.
- 27 February 2023
- Published by Springer Nature in Cell and Tissue Banking
- Vol. 25 (1) , 11-26
Open AccessLast twenty-years activity of cardiovascular tissue banking in Barcelona
The Barcelona Tissue Bank was established from the merge of two previous multi-tissue banks. Potential donors are screened by Donor Center staff and multi-tissue retrieval is performed by specialized own teams. Tissue processing and preservation is performed in clean room facilities by specialised personnel. After quality control of both donor and all tissues results, the heart valves and vascular segments are stored until medical request. The aim of this report is to present the cardiovascular tissue activity and retrospectively evaluate the outcomes of the changes performed in last 20 years. Cardiovascular tissue from 4088 donors was received, specifically 3115 hearts and 2095 vascular segments were processed and evaluated. A total of 48% of the aortic valves, 68% of the pulmonary valves and 75% of the vascular segments were suitable for transplant. The main reason for discarding tissue was macroscopic morphology followed by microbiological results, for both valves and arteries. Altogether, 4360 tissues were distributed for transplantation: 2032 (47%) vascular segments, 1545 (35%) pulmonary valves and 781 (18%) aortic valves. The most common indication for aortic valve surgery was the treatment of endocarditis, while for pulmonary valves, it was congenital malformation reconstruction. Vascular segments were mainly used for reconstruction after ischemia. During this period, a number of changes were made with the goal of enhancing tissue quality, safety and efficacy. These improvements were achieved through the use of a new antibiotic cocktail, increasing of donor age criteria and changing the microbiological control strategy.
- 1 October 2021
- Published by Elsevier in Tissue and Cell
- Vol. 72, 101572
Fast protocol for the processing of split-thickness skin into decellularized human dermal matrix
- 1 October 2021
- Published by Elsevier in Tissue and Cell
- Vol. 72, 101572
Fast protocol for the processing of split-thickness skin into decellularized human dermal matrix